Publications, Pharmaceutical

Evaluation of Albuterol Sulfate with Low Global Warming Potential Propellants

Reformulating widely used inhaled medications with propellants with a lower global warming potential is an important strategy for improving the sustainability of respiratory therapies.

This paper presents experimental data for a reformulated propellant-only formulation of albuterol sulfate in HFA-152a, a relatively low global warming potential propellant. Aerodynamic particle size distribution data were generated and used to predict regional deposition of the albuterol sulfate. Drug absorption was predicted using a pharmacokinetic model. The results demonstrate the feasibility of producing a stable pressurized metered dose inhaler formulation of albuterol sulfate using HFA-152a. Central deposition behavior was observed to be comparable to a current commercial product (Ventolin).

Download Publication
15 May 2021

Learn more about Aptar Pharma Expertise
in Pulmonary Drug Delivery

Find Out More

This Might Also Be of Interest

3 Jul 2023

Leachables Assessment: New pMDI with Low-GWP Propellants

Publications, Pharmaceutical, Sustainability, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
3 Jul 2023

Performance of Low-GWP Propellants in pMDIs: Filling and Dose Evaluation

Publications, Pharmaceutical, Product Solutions, Sustainability, Device Innovations, Market Insights

Read More
3 Jul 2023

Orally Inhaled Drug products; Bioequivalence Models

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations, Brand Differentiation

Read More
10 May 2023

Navigating the Development for Orally Inhaled and Nasal Drug Products

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
1 2 3 17
Back To Top